1. Home
  2. PRPL vs AKTX Comparison

PRPL vs AKTX Comparison

Compare PRPL & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$2.53

Market Cap

13.9M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$9.70

Market Cap

15.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
AKTX
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
15.4M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
PRPL
AKTX
Price
$2.53
$9.70
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$0.65
★ $33.50
AVG Volume (30 Days)
55.1K
★ 89.2K
Earning Date
04-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 152.75
N/A
EPS
N/A
★ N/A
Revenue
★ $468,725,000.00
N/A
Revenue This Year
$8.50
N/A
Revenue Next Year
$6.68
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.28
$0.12
52 Week High
$10.00
$29.32

Technical Indicators

Market Signals
Indicator
PRPL
AKTX
Relative Strength Index (RSI) 32.97 N/A
Support Level $0.49 N/A
Resistance Level $10.00 N/A
Average True Range (ATR) 0.29 0.00
MACD -0.02 0.00
Stochastic Oscillator 18.87 0.00

Price Performance

Historical Comparison
PRPL
AKTX

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: